US court of appeals upholds ruling in favour of Hikma over Vascepa
3rd Sep 2020 18:38
(Sharecast News) - US courts ruled against an appeal by Amarin related to Hikma Pharmaceuticals's generic treatment for heart conditions, Vascepa.
Read moreHikma raises sales guidance as profits rise on Covid-related demand
7th Aug 2020 07:48
(Sharecast News) - Hikma Pharmaceuticals lifted sales guidance for its injectables business on the back of higher demand for key medicines during the coronavirus pandemic as it reported a rise in interim profits.
Read moreTuesday broker round-up
7th Jul 2020 14:00
(Sharecast News) - Unite Group: Peel Hunt upgrades to add with a target price of 1,000.0p.
Read moreHikma Pharmaceuticals slumps as Boehringer Ingelheim sells stake
23rd Jun 2020 08:19
(Sharecast News) - Hikma Pharmaceuticals shares slumped on Tuesday after major shareholder German pharmaceutical group Boehringer Ingelheim sold off its 16.5% stake in the company.
Read moreSunday share tips: Hikma Pharmaceuticals, Vinacapital Vietnam Opportunity Fund
7th Jun 2020 12:37
(Sharecast News) - The Sunday Times's Sabah Meddings told readers to 'buy' shares of Hikma Pharmaceuticals, touting it as a potential beneficiary of the White House's 'America First' strategy to promote US manufacturing.
Read moreHikma gets FDA approval for generic version of 'Vascepa'
22nd May 2020 07:33
(Sharecast News) - Hikma Pharmaceuticals announced on Friday that its wholly-owned US subsidiary has received approval from the US Food and Drug Administration (FDA) for its icosapent ethyl capsules at one gram, which is its generic equivalent to 'Vascepa'.
Read moreHikma confident on outlook as sales rise in crisis
30th Apr 2020 08:20
(Sharecast News) - Hikma Pharmaceuticals said it was confident in its outlook for the year as the company sold more products during the Covid-19 crisis.
Read moreFriday broker round-up
24th Apr 2020 13:45
(Sharecast News) - Beazley: Jefferies upgrades to buy with a target price of 575p.
Read moreFriday broker round-up
3rd Apr 2020 12:35
(Sharecast News) - National Grid: Deutsche Bank downgrades to hold with a target price of 910p.
Read moreThursday broker round-up
2nd Apr 2020 13:03
(Sharecast News) - Unilever: Barclays upgrades to equal weight with a target price of 4,420p.
Read moreJP Morgan ups rating on Hikma after key patent win
2nd Apr 2020 12:11
(Sharecast News) - JP Morgan has upped its rating on Hikma Pharmaceuticals after the generics specialist won a key patent challenge.
Read moreHikma wins US patent case
31st Mar 2020 08:43
(Sharecast News) - Generic drugmaker Hikma Pharmaceuticals said on Tuesday that the US District Court of Nevada had ruled that its version of Amarin Corporation's Vascepa did not infringe six patents.
Read moreHikma posts decent results as it signs 'Ryaltris' deal with Glenmark
27th Feb 2020 07:29
(Sharecast News) - Hikma Pharmaceuticals reported a 6% improvement in group core revenue in its preliminary results on Thursday, to $2.2bn (£1.7bn).
Read moreThursday broker round-up
20th Feb 2020 13:40
(Sharecast News) - Travis Perkins: Citigroup upgrades to buy with a target price of 1,900p.
Read moreMonday broker round-up
17th Feb 2020 13:05
(Sharecast News) - Hikma Pharmatheuticals: Citigroup downgrades to neutral with a target price of 1,980p.
Read more